Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
119-HRES-1285119th CongressIntroduced May 14, 2026Health
Market Probability
No market
Status
Introduced
Committee
Floor Vote
Other Chamber
Signed
Referred to the House Committee on Energy and Commerce.
Sponsor
Rep. DeGette, Diana [D-CO-1](D-CO-1)52 cosponsors
Actions (4)
Referred to the House Committee on Energy and Commerce.
May 14, 2026House floor actions
Submitted in House
May 14, 2026Library of Congress
Submitted in House
May 14, 2026House floor actions
Submitted in House
May 14, 2026Library of Congress